Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer: Final results from a phase II trial

1. Sánchez-Rovira, P.
2. Jaén, A.
3. González, E.
4. Porras, I.
5. Dueñas, R.
6. Medina, B.
7. Mohedano, N.
8. Fernández, M.
9. Marios, M.
10. Lozano, A.
11. Carrasco, E.